Niall Buckley1, Ashley Huber1, Yungtai Lo2, Philip E Castle2, Kimdar Kemal1, Robert D Burk1,2, Howard D Strickler2, Mark H Einstein3, Mary Young4, Kathryn Anastos5, Betsy C Herold1,3,6. 1. Department of Pediatrics, Albert Einstein College of Medicine, Bronx, NY, USA. 2. Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA. 3. Department of Obstetrics & Gynecology and Women's Health, Albert Einstein College of Medicine, Bronx, NY, USA. 4. Department of Medicine, Georgetown University, Washington, DC, USA. 5. Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA. 6. Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA.
Abstract
PROBLEM: High-risk human papillomavirus (HR-HPV) is prevalent in HIV-infected women and may be associated with mucosal changes that promote HIV replication. METHOD OF STUDY: Innate immune molecules, antimicrobial activity, HIV RNA, and HPV DNA genotypes were measured in a cross-sectional study of 128 HIV-infected women categorized into HPV-16 (n = 8), other HR-HPV (n = 41), and non-HR-HPV controls (n = 79). RESULTS: Compared to controls, HR-HPV groups had higher plasma viral loads (P = 0.004), lower CD4 cells (P = 0.02), more genital tract HIV RNA (P = 0.03), greater number of different HPV types (P < 0.001), higher cervicovaginal lavage (CVL) IL-1α (P = 0.03) and human beta-defensin 2 (HBD2) (P = 0.049), and less anti-HIVB al activity (P = 0.03). HPV-16 remained significantly associated with higher HBD2 (P = 0.03), higher IL-1α (P = 0.009), and lower anti-HIVB aL activity (P = 0.03) compared to controls after adjusting for plasma viral load and CD4 T cell count. CONCLUSION: HR-HPV is associated with mucosal changes in HIV-infected women that could adversely impact genital tract health.
PROBLEM: High-risk human papillomavirus (HR-HPV) is prevalent in HIV-infectedwomen and may be associated with mucosal changes that promote HIV replication. METHOD OF STUDY: Innate immune molecules, antimicrobial activity, HIV RNA, and HPV DNA genotypes were measured in a cross-sectional study of 128 HIV-infectedwomen categorized into HPV-16 (n = 8), other HR-HPV (n = 41), and non-HR-HPV controls (n = 79). RESULTS: Compared to controls, HR-HPV groups had higher plasma viral loads (P = 0.004), lower CD4 cells (P = 0.02), more genital tract HIV RNA (P = 0.03), greater number of different HPV types (P < 0.001), higher cervicovaginal lavage (CVL) IL-1α (P = 0.03) and humanbeta-defensin 2 (HBD2) (P = 0.049), and less anti-HIVB al activity (P = 0.03). HPV-16 remained significantly associated with higher HBD2 (P = 0.03), higher IL-1α (P = 0.009), and lower anti-HIVB aL activity (P = 0.03) compared to controls after adjusting for plasma viral load and CD4 T cell count. CONCLUSION:HR-HPV is associated with mucosal changes in HIV-infectedwomen that could adversely impact genital tract health.
Authors: Melanie C Bacon; Viktor von Wyl; Christine Alden; Gerald Sharp; Esther Robison; Nancy Hessol; Stephen Gange; Yvonne Barranday; Susan Holman; Kathleen Weber; Mary A Young Journal: Clin Diagn Lab Immunol Date: 2005-09
Authors: Lingling Sun; Catherine M Finnegan; Tina Kish-Catalone; Robert Blumenthal; Paolo Garzino-Demo; Gian M La Terra Maggiore; Sid Berrone; Carol Kleinman; Zhibin Wu; Sayed Abdelwahab; Wuyuan Lu; Alfredo Garzino-Demo Journal: J Virol Date: 2005-11 Impact factor: 5.103
Authors: Howard D Strickler; Robert D Burk; Melissa Fazzari; Kathryn Anastos; Howard Minkoff; L Stewart Massad; Charles Hall; Melanie Bacon; Alexandra M Levine; D Heather Watts; Michael J Silverberg; Xiaonan Xue; Nicolas F Schlecht; Sandra Melnick; Joel M Palefsky Journal: J Natl Cancer Inst Date: 2005-04-20 Impact factor: 13.506
Authors: Tiffany G Harris; Robert D Burk; Joel M Palefsky; L Stewart Massad; Ji Yon Bang; Kathryn Anastos; Howard Minkoff; Charles B Hall; Melanie C Bacon; Alexandra M Levine; D Heather Watts; Michael J Silverberg; Xiaonan Xue; Sandra L Melnick; Howard D Strickler Journal: JAMA Date: 2005-03-23 Impact factor: 56.272
Authors: S E Barkan; S L Melnick; S Preston-Martin; K Weber; L A Kalish; P Miotti; M Young; R Greenblatt; H Sacks; J Feldman Journal: Epidemiology Date: 1998-03 Impact factor: 4.822
Authors: B C Herold; A Siston; J Bremer; R Kirkpatrick; G Wilbanks; P Fugedi; C Peto; M Cooper Journal: Antimicrob Agents Chemother Date: 1997-12 Impact factor: 5.191
Authors: Minnie John; Marla J Keller; Ehsan H Fam; Natalia Cheshenko; Kathleen Hogarty; Andrea Kasowitz; Sylvan Wallenstein; Maria J Carlucci; Ana C Tuyama; Wuyuan Lu; Mary E Klotman; Robert I Lehrer; Betsy C Herold Journal: J Infect Dis Date: 2005-10-13 Impact factor: 5.226
Authors: Akiko Kobayashi; Ruth M Greenblatt; Kathryn Anastos; Howard Minkoff; Leslie S Massad; Mary Young; Alexandra M Levine; Teresa M Darragh; Vivian Weinberg; Karen K Smith-McCune Journal: Cancer Res Date: 2004-09-15 Impact factor: 12.701
Authors: Julie A E Nelson; Kristina De Paris; Catalina Ramirez; Andrew Edmonds; Katie R Mollan; Camden P Bay; Kara Compliment; Betsy C Herold; Kathryn Anastos; Howard Minkoff; Seble Kassaye; Dominika L Seidman; Audrey L French; Elizabeth T Golub; Anandi N Sheth; Christina Ochsenbauer; Ronald Swanstrom; Joseph J Eron; Adaora A Adimora Journal: AIDS Date: 2020-01-01 Impact factor: 4.632
Authors: Theresa Rossouw; Joseph D Tucker; Gert U van Zyl; Kenly Sikwesi; Catherine Godfrey Journal: J Int AIDS Soc Date: 2017-06-05 Impact factor: 5.396
Authors: Raina N Fichorova; Charles S Morrison; Pai-Lien Chen; Hidemi S Yamamoto; Yashini Govender; Damilola Junaid; Stanthia Ryan; Cynthia Kwok; Tsungai Chipato; Robert A Salata; Gustavo F Doncel Journal: PLoS One Date: 2020-01-08 Impact factor: 3.240